TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
Xue-Yan ChenBing-Xi YanXiao-Yong ManPublished in: Therapeutic advances in respiratory disease (2020)
Increased inflammatory cytokines [such as tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6)] are observed in COVID-19 patients, especially in the severe group. The phenomenon of a cytokine storm may be the central inducer of apoptosis of alveolar epithelial cells, which leads to rapid progression in severe group patients. Given the similarities of clinical features and pathogenesis between toxic epidermal necrolysis (TEN) and COVID-19, we hypothesize that the application of etanercept, an inhibitor of TNFα, could attenuate disease progression in severe group COVID-19 patients by suppressing systemic auto-inflammatory responses. The reviews of this paper are available via the supplemental material section.
Keyphrases
- sars cov
- rheumatoid arthritis
- coronavirus disease
- early onset
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oxidative stress
- drug induced
- cell death
- prognostic factors
- randomized controlled trial
- systematic review
- ankylosing spondylitis
- endoplasmic reticulum stress
- disease activity
- signaling pathway
- cell proliferation
- juvenile idiopathic arthritis
- wound healing
- pi k akt